

SEQUENCE LISTING

<110> OKU, TADATAKE
NISHIO, TOSHIYUKI
KAWACHI, RYU
SURUGA, KOHEI

<120> NOVEL HEME PEPTIDE

<130> N0008.0001

<140> 10/507,156

<141> 2004-09-07

<150> PCT/JP03/02394

<151> 2003-02-28

<150> JP 2002-058086

<151> 2002-03-04

<160> 18

<170> PatentIn Ver. 3.2

<210> 1

<211> 104

<212> PRT

<213> Equus caballus

<400> 1

Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Val Gln Lys Cys Ala Gln
1 5 10 15

Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn Leu
20 25 30

His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Phe Thr Tyr
35 40 45

Thr Asp Ala Asn Lys Asn Lys Gly Ile Thr Trp Lys Glu Glu Thr Leu
50 55 60

Met Glu Tyr Leu Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys Met
65 70 75 80

Ile Phe Ala Gly Ile Lys Lys Lys Thr Glu Arg Glu Asp Leu Ile Ala
85 90 95

Tyr Leu Lys Lys Ala Thr Asn Glu
100

<210> 2

<211> 85

<212> PRT

<213> Porphyra yezoensis

<400> 2

Ala Asp Leu Asp Asn Gly Glu Lys Val Phe Ser Ala Asn Cys Ala Ala
1 5 10 15

Cys His Ala Gly Gly Asn Asn Ala Ile Met Pro Asp Lys Thr Leu Lys
20 25 30

Lys Asp Val Leu Glu Ala Asn Ser Met Asn Thr Ile Asp Ala Ile Thr

35 40 45
 Tyr Gln Val Gln Asn Gly Lys Asn Ala Met Pro Ala Phe Gly Gly Arg
 50 55 60
 Leu Val Asp Glu Asp Ile Glu Asp Ala Ala Asn Tyr Val Leu Ser Gln
 65 70 75 80
 Ser Glu Lys Gly Trp
 85

<210> 3
 <211> 15
 <212> PRT
 <213> *Porphyra yezoensis*

<400> 3
 Phe Ser Ala Asn Cys Ala Ala Cys His Ala Gly Gly Asn Asn Ala
 1 5 10 15

<210> 4
 <211> 9
 <212> PRT
 <213> *Equus caballus*

<400> 4
 Cys Ala Gln Cys His Thr Val Glu Lys
 1 5

<210> 5
 <211> 22
 <212> PRT
 <213> *Equus caballus*

<400> 5
 Val Gln Lys Cys Ala Gln Cys His Thr Val Glu Lys Gly Gly Lys His
 1 5 10 15

Lys Thr Gly Pro Asn Leu
 20

<210> 6
 <211> 65
 <212> PRT
 <213> *Equus caballus*

<400> 6
 Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Val Gln Lys Cys Ala Gln
 1 5 10 15

Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn Leu
 20 25 30

His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Phe Thr Tyr
 35 40 45

Thr Asp Ala Asn Lys Asn Lys Gly Ile Thr Trp Lys Glu Glu Thr Leu
 50 55 60

Met
 65

<210> 7
<211> 9
<212> PRT
<213> Equus caballus

<400> 7
Cys Ala Gln Cys His Thr Val Glu Lys
1 5

<210> 8
<211> 21
<212> PRT
<213> Porphyra yezoensis

<400> 8
Val Phe Ser Ala Asn Cys Ala Ala Cys His Ala Gly Gly Asn Asn Ala
1 5 10 15
Ile Met Pro Asp Lys
20

<210> 9
<211> 17
<212> PRT
<213> Equus caballus

<400> 9
Lys Gly Lys Lys Ile Phe Val Gln Lys Cys Ala Gln Cys His Thr Val
1 5 10 15
Glu

<210> 10
<211> 29
<212> PRT
<213> Porphyra yezoensis

<400> 10
Val Phe Ser Ala Asn Cys Ala Ala Cys His Ala Gly Gly Asn Asn Ala
1 5 10 15
Ile Met Pro Asp Lys Thr Leu Lys Lys Asp Val Leu Glu
20 25

<210> 11
<211> 75
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Formula
peptide

<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> this region may encompass a hydrogen atom or 1-20 variable
amino acids

<220>
<221> MISC_FEATURE
<222> (22)..(23)
<223> any amino acid

<220>
<221> MISC_FEATURE
<222> (25)
<223> His, Lys or Arg

<220>
<221> MISC_FEATURE
<222> (26)..(75)
<223> this region may encompass a hydroxyl group or 1-50 variable amino acids

<220>
<223> see specification as filed for detailed description of preferred embodiments

<400> 11
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75

<210> 12
<211> 75
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Formula peptide

<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> this region may encompass a hydrogen atom or 1-20 variable amino acids

<220>
<221> MISC_FEATURE
<222> (22)..(23)
<223> Ala, Gln, Lys, Arg or Val

<220>
<221> MISC_FEATURE
<222> (25)
<223> His, Lys or Arg

<220>
<221> MISC_FEATURE
<222> (26)..(75)
<223> this region may encompass a hydroxyl group or 1-50 variable

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75

<210> 14
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 14
Thr Val Glu Lys

<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 15
Phe Ser Ala Asn
1

<210> 16
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 16
Ala Gly Gly Asn Asn Ala
1 5

<210> 17
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MISC_FEATURE
<222> (1)..(3)
<223> this region may encompass a hydrogen atom

<400> 17
Val Glu Lys Cys Ala Glu Cys His Thr Val Glu
1 5 10

<210> 18

<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 18
Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn Leu
1 5 10